Skip to main content
. 2018 Jan 15;10(1):86–100.

Figure 6.

Figure 6

Relationship between cAMP-PKA and the Src pathway. Osteoblasts were pre-treated with melatonin (2 mM) and/or the Src inhibitor PP2 (20 μM) for 24 h. Levels of cAMP were then assessed by ELISA, and data are presented as the percent optical density relative to controls (untreated). Melatonin decreased cAMP, but treatment with PP2 had no additional effects. Experiments were performed in triplicate, and data are shown as the mean ± S.E.M. **P < 0.01, compared to control cells.